Compare IDEXX Laboratories, Inc. (IDXX) vs Marathon Petroleum Corp (MPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Marathon Petroleum Corp — how do they compare? IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B), while Marathon Petroleum Corp trades at $348.55 (market cap $94.48B). The key difference: Marathon Petroleum Corp is far larger — about 2× IDEXX Laboratories, Inc.'s market cap, and Marathon Petroleum Corp pays a 1.19% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | MPC | |
|---|---|---|
Market Cap | $46.22B | $94.48B |
Sector | Health | Energy |
52-Week High | $766.68 | $336.42 |
52-Week Low | $526.44 | $159.11 |
Enterprise Value | $47.12B | $121.00B |
Dividend Yield | — | 1.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
Marathon Petroleum (MPC) trades at $345.68, up 7.92% over 24 hours, with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with a P/E of 11.67 and ROE of 47.9%, supported by recent earnings beats including Q2 2026 EPS of $17.73 versus $14.27 expected. Refining margins remain elevated due to global supply constraints, driving revenue growth projections to $153.6B for 2026.
MPC presents a compelling investment case with strong cash flow generation and shareholder returns via dividends and buybacks. Key risks include exposure to volatile energy markets and geopolitical factors affecting refining margins. Wall Street maintains strong bullish consensus with 76% buy ratings and $332.70 price target, though current price exceeds consensus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →
